Find Clinical Trial

Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). – CALM study


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

IndicationBlood cancer
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

UCART19,
S068587

Active Substance CodeS068587
Protocol CodeCL1-68587-002
EudraCT Code2016-000296-24
NCT CodeNCT02746952


Documents and links

Lay summary
Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



More information

UCART-19  is anti-CD-19 allogenic CAR-T product developed based on exclusive license granted by Cellectis to Servier. UCART-19 uses Cellectis’ technologies, including TALEN® gene-editing technologies

© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility